Antiganglioside antibody frequency in routine clinical care settings
European Journal of Neurology · 2024
DOI: 10.1111/ene.16290 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Niklas Giesche und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epileptology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Gangliosides, Autoantibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Tuebingen.
Abstract (Originalsprache)
Background and purpose Antiganglioside antibodies (AGAs) might be involved in the etiopathogenesis of many neurological diseases, such as Miller–Fisher syndrome (MFS) and Guillain–Barré syndrome (GBS). Available comprehensive reference data regarding AGA positivity rates and cross‐responsiveness among AGAs (where one line immunoblot is positive for ≥1 AGA) during routine clinical care are scant.
Methods
In this 10‐year monocentric retrospective study, 3560 immunoglobulin (Ig) G and IgM line blots (GA Generic Assays' Anti‐Ganglioside Dot kit) obtained using cerebrospinal fluid (CSF) and serum samples from 1342 patients were analyzed for AGA positivity in terms of 14 diagnosis categories and AGA cross‐responsiveness.
Results
Of all 3560 line blots 158 (4.4%) and of all CSF samples 0.4% (4/924) CSF line blots were AGA positive. For serum IgG, blots with positivity rates higher than the standard deviation of 15.6% were associated with MFS (GD3, GD1a, GT1a and GQ1b) and acute motor axonal neuropathy (AMAN) (GM1, GD1a and GT1a). For serum IgM, blots with positivity rates higher than the standard deviation of 8.1% were associated with AMAN (GM2, GT1a and GQ1b), MFS (GM1, GT1a and GQ1b), multifocal motor neuropathy (MMN) (GM1, GM2 and GQ1b) and chronic inflammatory demyelinating polyneuropathy (CIDP) (GM1). Cross‐responsiveness was observed in 39.6% of all positive serum AGA.
Conclusions
Testing for AGAs during routine clinical care rarely led to positive findings, both in serum and even less in CSF, except for the diagnoses AMAN, MFS, MMN and CIDP. Nonspecific findings found as cross‐responsiveness between different AGA samples occur frequently, impacting the positivity of most AGA subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epileptology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
- Department of Neurology and Stroke, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
- Department of Neural Dynamics and Magnetoencephalography, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
- MEG-Center, University of Tübingen, Tübingen, Germany.
- Institute for Modelling and Simulation of Biomechanical Systems, Stuttgart, Germany.
ORCID-Profile: Benedict Kleiser, Alexander Grimm, Justus Marquetand
Förderung
- University of Tuebingen
Zitieren
APA
Giesche, N., Böhm-Gonzalez, S. T., Kleiser, B., Kowarik, M. C., Dubois, E., Stransky, E., Armbruster, M., Grimm, A., & Marquetand, J. (2024). Antiganglioside antibody frequency in routine clinical care settings. European Journal of Neurology. https://doi.org/10.1111/ene.16290
Vancouver
Giesche N, Böhm-Gonzalez ST, Kleiser B, Kowarik MC, Dubois E, Stransky E, et al. Antiganglioside antibody frequency in routine clinical care settings. European Journal of Neurology. 2024. doi:10.1111/ene.16290
BibTeX
@article{Giesche2024,
author = {Giesche, Niklas and Böhm-Gonzalez, Samuel Tobias and Kleiser, Benedict and Kowarik, Markus C and Dubois, Evelyn and Stransky, Elke and Armbruster, Marcel and Grimm, Alexander and Marquetand, Justus},
title = {Antiganglioside antibody frequency in routine clinical care settings},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16290}
}
EUVIMED